Clinical Trials Logo

ER+ HER2- Advanced Breast Cancer clinical trials

View clinical trials related to ER+ HER2- Advanced Breast Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03596658 Terminated - Clinical trials for ER+ HER2- Advanced Breast Cancer

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1 open label multicentre study of SHR9549 administered orally in patients with advanced estrogen receptor (ER) positive human epidermal receptor 2 (HER2) negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose(MTD). In addition, expansion cohort(s) at potential therapeutic dose(s) in patients will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of SHR9549.